Table 1.

The current state of knowledge of EGFR mutations in patients with NSCLC

KnownUnknown
EGFR mutations are associated with responses to gefitinib and erlotinibThe etiology of the EGFR mutations
EGFR mutations are somaticThe relative oncogenic properties of the different EGFR mutations
EGFR mutations are more common in women, nonsmokers, in adenocarcinomas, and East AsiansThe outcome of patients with different EGFR mutation treated with different EGFR-TKIs
Secondary EGFR mutations are associated with resistance to gefitinib and erlotinib in patients and in vitroThe mechanisms of resistance to gefitinib and erlotinib in the patients who do not have the identified T790M secondary EGFR mutation